166 related articles for article (PubMed ID: 18182133)
21. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
Shazad B; Abbaszadeh B; Khamesipour A
Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
[TBL] [Abstract][Full Text] [Related]
22. Comparison of skin smears and biopsy specimens for demonstration of Leishmania tropica bodies in cutaneous leishmaniasis.
Dar NR; Khurshid T
J Coll Physicians Surg Pak; 2005 Dec; 15(12):765-7. PubMed ID: 16398966
[TBL] [Abstract][Full Text] [Related]
23. Delayed allergic skin reactions due to intralesional meglumine antimoniate therapy for cutaneous leishmaniasis.
Córdoba S; Gandolfo Cano M; Aguado M; Huerta-Brogera M; Romero A; Martínez-Morán C; Borbujo J
Allergy; 2012 Dec; 67(12):1609-11. PubMed ID: 23067046
[TBL] [Abstract][Full Text] [Related]
24. Comparison of lesion improvement in lupoid leishmaniasis patients with two treatment approaches: trichloroacetic Acid and intralesional meglumine antimoniate.
Banihashemi M; Yazdanpanah MJ; Amirsolymani H; Yousefzadeh H
J Cutan Med Surg; 2015; 19(1):35-9. PubMed ID: 25775661
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis.
Kashani MN; Firooz A; Eskandari SE; Ghoorchi MH; Khamesipour A; Khatami A; Javadi A; Dowlati Y
Eur J Dermatol; 2007; 17(6):513-5. PubMed ID: 17951131
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
Layegh P; Yazdanpanah MJ; Vosugh EM; Pezeshkpoor F; Shakeri MT; Moghiman T
Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637
[TBL] [Abstract][Full Text] [Related]
27. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.
Mlika RB; Hamida MB; Hammami H; Jannet SB; Badri T; Fenniche S; Mokhtar I
Dermatol Ther; 2012; 25(6):615-8. PubMed ID: 23210761
[TBL] [Abstract][Full Text] [Related]
28. Comparison of oral zinc sulfate with systemic meglumine antimoniate in the treatment of cutaneous leishmaniasis.
Yazdanpanah MJ; Banihashemi M; Pezeshkpoor F; Khajedaluee M; Famili S; Tavakoli Rodi I; Yousefzadeh H
Dermatol Res Pract; 2011; 2011():269515. PubMed ID: 21747837
[TBL] [Abstract][Full Text] [Related]
29. Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
Esfandiarpour I; Farajzadeh S; Rahnama Z; Fathabadi EA; Heshmatkhah A
Int J Dermatol; 2012 Oct; 51(10):1221-5. PubMed ID: 22994669
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of miltefosine in cutaneous leishmaniasis: An open label, non-comparative study from Balochistan.
Tahir M; Bashir U; Hafeez J; Ghafoor R
Pak J Med Sci; 2019; 35(2):495-499. PubMed ID: 31086539
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous lupoid leishmaniasis: a case report.
Ferahbaş A; Mistik S; Utaş S; Yaman O; Canoz O; Doganay M; Aşçioglu O
Cutis; 2006 Jan; 77(1):25-8; quiz 37-8. PubMed ID: 16475491
[TBL] [Abstract][Full Text] [Related]
32. Childhood leishmaniasis: report of 106 cases.
Kharfi M; Benmously R; El Fekih N; Daoud M; Fitouri Z; Mokhtar I; Ben Becher S; Kamoun MR
Dermatol Online J; 2004 Oct; 10(2):6. PubMed ID: 15530296
[TBL] [Abstract][Full Text] [Related]
33. Comparative Efficacy of Intralesional Chloroquine With Intralesional Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.
Ullah O; Rizwan M; Raza N; Zulfiqar S; Akbar N; Ullah H
Cureus; 2024 Mar; 16(3):e56785. PubMed ID: 38650776
[TBL] [Abstract][Full Text] [Related]
34. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
[TBL] [Abstract][Full Text] [Related]
35. Double blind, randomized controlled trial, to evaluate the effectiveness of a controlled nitric oxide releasing patch versus meglumine antimoniate in the treatment of cutaneous leishmaniasis [NCT00317629].
Silva SY; Rueda LC; López M; Vélez ID; Rueda-Clausen CF; Smith DJ; Muñoz G; Mosquera H; Silva FA; Buitrago A; Díaz H; López-Jaramillo P
Trials; 2006 May; 7():14. PubMed ID: 16700912
[TBL] [Abstract][Full Text] [Related]
36. Childhood cutaneous leishmaniasis: Experience of a Moroccan unit of dermatology.
Qasmi S; Elguelbazouri N; Belgnaoui FZ; Marcil T; Bouhllab J; Senouci K; Aitourhoui M; Hassam B
Dermatol Online J; 2008 Dec; 14(12):18. PubMed ID: 19265631
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis.
Nassiri-Kashani M; Firooz A; Khamesipour A; Mojtahed F; Nilforoushzadeh M; Hejazi H; Bouzari N; Dowlati Y
J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):80-3. PubMed ID: 15649196
[TBL] [Abstract][Full Text] [Related]
38. Effect of hydroalcoholic extract of
Sarkari B; Mohseni M; Moein MR; Shahriarirad R; Asgari Q
Int J Appl Basic Med Res; 2017; 7(1):53-56. PubMed ID: 28251109
[TBL] [Abstract][Full Text] [Related]
39. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
[TBL] [Abstract][Full Text] [Related]
40. Unusual form of cutaneous leishmaniasis: erysipeloid form.
Mnejja M; Hammami B; Chakroun A; Achour I; Charfeddine I; Chakroun A; Turki H; Ghorbel A
Eur Ann Otorhinolaryngol Head Neck Dis; 2011 Apr; 128(2):95-7. PubMed ID: 21251895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
